ArticleEuropean urology2020

Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study.

Yiannis Philippou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.